By staff writers

June 8, 2009 -- Molecular imaging and therapy developer Aposense of Petach-Tikva, Israel, is collaborating with British pharmaceutical firm GlaxoSmithKline (GSK) to evaluate the potential of Aposense's ML-10 PET tracer in monitoring drug activity in clinical studies of cancer therapies.

The project is intended to assess ML-10's contribution in accelerating clinical development of cancer therapies. The initial term of the nonexclusive collaboration with GSK is for two years and can be extended on certain conditions. Financial terms were not disclosed.

Aposense begins trial, December 15, 2008

NeuroSurvival Technologies gets financing, changes name, August 20, 2008

IBA, NeuroSurvival Technologies partner, August 14, 2008

NST is cleared for Aposense trials, July 25, 2008

Copyright © 2009


To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking